Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2007

Martinez-Salamanca JI, Rao S, Ramanathan R, Gonzalez J, Mandhani A, Yang X, et al. Nerve advancement with end-to-end reconstruction after partial neurovascular bundle resection:a feasibility study. J Endourol. 2007;21(8):830-5.

Berlingieri MT, Pallante P, Guida M, Nappi C, Masciullo V, Scambia G, et al. UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. Oncogene. 2007;26(14):2136-40.

Jaggi JS, Henke E, Seshan SV, Kappel BJ, Chattopadhyay D, May C, et al. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS One. 2007;2(3):e267.

Baumgart E, Cohen MS, Neto BS, Jacobs MA, Wotkowicz C, Rieger-Christ KM, et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res. 2007;13(6):1685-94.

Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19(1):3-9.

Cesarman E, Mesri EA. Kaposi sarcoma-associated herpesvirus and other viruses in human lymphomagenesis. Curr Top Microbiol Immunol. 2007;312:263-87.

Woon CS, Pambuccian SE, Lai R, Jessurun J, H Gulbahce E. Ciliated foregut cyst of pancreas: cytologic findings on endoscopic ultrasound-guided fine-needle aspiration. Diagn Cytopathol. 2007;35(7):433-8.

Zapata M, Cohen C, Siddiqui MT. Immunohistochemical expression of SMAD4, CK19, and CA19-9 in fine needle aspiration samples of pancreatic adenocarcinoma: Utility and potential role. Cytojournal. 2007;4:13.

Li R, Todd NW, Qiu Q, Fan T, Zhao RY, Rodgers WH, et al. Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer. Clin Cancer Res. 2007;13(2 Pt 1):482-7.

Heymann JJ, Benson MC, O'Toole KM, Malyszko B, Brody R, Vecchio D, et al. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. J Clin Oncol. 2007;25(1):77-84.